Coya Therapeutics, Inc. (COYA)
COYANASDAQ-CMBiotechnology: Pharmaceutical Preparations
$3.21
+0.1200 (+3.88%) today
Pre-market, Nov 11, 4:00 PM ET
- Market cap
- $75.30m
- P/E
- –
- EPS, last 4 quarters
- $-1.39
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.72 to $6.62
- Average volume
- –
- Previous close
- $3.09
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $15.75, +390.7% from here
Earnings
next estimate $-0.3900Next report
Dec 2025
-325.0%
Mar 2026
+17.9%
Jun 2026
+22.2%
Sep 2026
-28.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $3.96m | $251.0k | $244.0k | $234.0k |
| Gross profit | $3.96m | $251.0k | $244.0k | $234.0k |
| Operating income | -$6.03m | -$7.64m | -$7.05m | -$10.95m |
| Net income | -$5.71m | -$7.21m | -$6.64m | -$10.62m |
Last four quarters: revenue $4.69m, margin -643.5%, free cash flow –
News
8 latest- Coya Therapeutics Reports Wider Q3 Loss; Expects Phase 2/3 ALSTARS ALS Data In Q2 2027 RTTNews · 1 day ago
- Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?Zacks · Jun 30, 2026
- Coya Therapeutics: COYA 302 Receives FDA Fast Track Designation For Treatment Of ALS RTTNews · May 12, 2026
- Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?Zacks · Feb 25, 2026
- D. Boral Capital Maintains Coya Therapeutics (COYA) Buy RecommendationFintel · Dec 23, 2025
- D. Boral Capital Maintains Coya Therapeutics (COYA) Buy RecommendationFintel · Dec 9, 2025
- Chardan Capital Maintains Coya Therapeutics (COYA) Buy RecommendationFintel · Nov 14, 2025
- BTIG Maintains Coya Therapeutics (COYA) Buy RecommendationFintel · Nov 13, 2025
The company
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ('Tregs') to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- coyatherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.